EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

Takashi Yokokawa iD, Daiki Tsuji iD, Masahiro Hatori iD, Kazuyoshi Kawakami iD, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi iD, Masato Ozaka, Naoki Sasahira iD, Yasuhiko Sakata und 10 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Takashi Yokokawa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Pancreatic Neoplasms, ATP-Binding Cassette, Sub-Family C Proteins, Antimetabolites, Antineoplastic. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Research Foundation for Clinical Pharmacology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM. The present study was a sub‐analysis including only GEM monotherapy patients.

Methods

Of 159 patients analysed in the GENESECT study, only GEM‐monotherapy patients were selected. The endpoints included carbohydrate antigen 19‐9 (CA19‐9) response (reduction ≥ 50% from the pretreatment level at 8 weeks), progression‐free survival (PFS), and overall survival (OS) in relation to GPs. Analysed genes included those encoding GEM transporters and metabolic enzymes ( SLC29A1 , ABCC5 , CDA , DCK , RRM1/2 ) and a tumour cell proliferation enzyme ( COX‐2 ). Screening and significance levels were set at 10% (univariable) and 5% (multivariable), respectively.

Results

Data for 50 patients were analysed. Genotype AA of ABCC5 1146A>G (rs7636910) showed a higher CA19‐9 response rate than AG/GG (52.9% vs. 21.2%, p = 0.023) and remained significant in multivariable analysis (odds ratio: 6.255, p = 0.014). It also tended to be associated with longer PFS, but not significantly (hazard ratio [HR]: 0.464, p = 0.074). By contrast, although CA19‐9 responses were not significantly associated with DCK −1205T>C (rs4694362), the TT/TC genotype was significantly associated with prolonged PFS compared with CC (median 127 vs. 48 days, p = 0.002), and this association remained significant in multivariable analysis (HR: 0.153, p = 0.028). No GPs were significantly associated with OS.

Conclusion

ABCC5 and DCK might be related to the efficacy of GEM treatment, but further research is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidinePancreatic NeoplasmsATP-Binding Cassette, Sub-Family C ProteinsAntimetabolites, AntineoplasticHumansGemcitabineFemaleMaleAgedMiddle AgedProgression-Free SurvivalPaclitaxelPharmacogenomic TestingPharmacogeneticsCA-19-9 AntigenPolymorphism, Single NucleotideGenotypeAdultAlbumins

Stichwörter der Autor:innen

clinical pharmacology, pharmacogenomicsclinical pharmacology, pharmacotherapygenetics and pharmacogenetics, canceroncologyoncology, anticancer drugs

Substanzen

DeoxycytidineGemcitabineATP-Binding Cassette, Sub-Family C ProteinsABCC5 protein, humanAntimetabolites, AntineoplasticPaclitaxelCA-19-9 Antigen130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  • Department of Pharmacy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  • Department of Pharmacy, Osaka City General Hospital, Osaka, Japan.
  • Department of Pharmacy, Sumitomo Besshi Hospital, Ehime, Japan.

ORCID-Profile: Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Yasukata Ohashi, Naoki Sasahira, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Kenichi Suzuki

Förderung

  • Japan Research Foundation for Clinical Pharmacology

Zitieren

APA

Yokokawa, T., Tsuji, D., Hatori, M., Kawakami, K., Nakao, M., Yano, T., Arakawa, Y., Matsuo, K., Ohashi, Y., Ozaka, M., Sasahira, N., Sakata, Y., Kogure, Y., Tamaki, S., Wada, A., Taki, Y., Suzuki, W., Kobayashi, K., Ishii, H., …, & Suzuki, K. (2026). Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70611

Vancouver

Yokokawa T, Tsuji D, Hatori M, Kawakami K, Nakao M, Yano T, et al. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70611

BibTeX
@article{Yokokawa2026,
  author = {Yokokawa, Takashi and Tsuji, Daiki and Hatori, Masahiro and Kawakami, Kazuyoshi and Nakao, Masahiko and Yano, Takuya and Arakawa, Yuichiro and Matsuo, Keisuke and Ohashi, Yasukata and Ozaka, Masato and Sasahira, Naoki and Sakata, Yasuhiko and Kogure, Yuki and Tamaki, Shinya and Wada, Atsushi and Taki, Yusuke and Suzuki, Wataru and Kobayashi, Kazuo and Ishii, Hiroshi and Itoh, Kunihiko and Yamaguchi, Masakazu and Suzuki, Kenichi},
  title = {Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70611}
}
Kostenlos starten →